Stem Cells SpinWAR:SCS 25 Buyback Yield % is 0.00 as of Jul. 05, 2026. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 741 Biotechnology companies, Stem Cells Spin ranks worse than 134952.63% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Stem Cells Spin's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCS vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Stem Cells Spin's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stem Cells Spin (WAR:SCS) has a Buyback Yield % of 0.00 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Stem Cells Spin and its competitors. According to the industry distribution chart, Stem Cells Spin ranks #999999 out of 741 companies in the Biotechnology industry.
Is Stem Cells Spin's Buyback Yield % too high?
Stem Cells Spin's current Buyback Yield % is 0.00. Based on the distribution chart, Stem Cells Spin ranks #999999 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #999999 out of 741 companies for Buyback Yield %. This places Stem Cells Spin in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Stem Cells Spin and its competitors. Stem Cells Spin's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current Buyback Yield % is 0.00. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current Buyback Yield % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
Buyback Yield %: 0.00
GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score
Get the complete analysis for WAR:SCS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
